Skip to content

Alprazolam

    DEA Class;  Rx

    Common Brand Names; Xanax, Niravam, Xanax XR

    • Antianxiety Agents; 
    • Anxiolytics, Benzodiazepine

    Oral intermediate-acting benzodiazepine with minimally active metabolites
    Approved for panic disorder, generalized anxiety disorder, and short-term treatment of anxiety symptoms in adults; rarely used in pediatric patients off-label
    Avoid coadministration with opioids if possible due to potential for profound sedation, respiratory depression, coma, and death

    Indicated for the short-term treatment of transient symptoms of anxiety.

    For the treatment of generalized anxiety disorder (GAD).
    For the treatment of panic disorder with or without agoraphobia.
    For the treatment of anxiety and mood-symptoms associated with premenstrual dysphoric disorder (PMDD) that is unresponsive to non-pharmacologic or preferred therapy.

    Documented hypersensitivity

    Acute narrow angle glaucoma

    Concomitant use with CYP3A4 inhibitors (itraconazole, ketoconazole)

    >10% (4 mg dose)

    • Drowsiness (41%)
    • Depression (10-15%)
    • Headache (10-15%)
    • Constipation (10-15%)
    • Diarrhea (10-15%)
    • Dry mouth (10-15%)

    >10% (10 mg dose)

    • Drowsiness (77%)
    • Impaired coordination (40-50%)
    • Increased appetite (30-35%)
    • Fatigue (30-35%)
    • Memory impairment (30-35%)
    • Irritability (30-35%)
    • Decreased salivation (30-35%)
    • Cognitive disorders (20-30%)
    • Insomnia (20-30%)
    • Dcreased appetite (20-30%)
    • Headache (20-30%)
    • Lightheadedness (20-30%)
    • Dysarthria (20-30%)
    • Diarrhea, constipation, and nausea/vomiting (20-30%)
    • Weight change (20-30%)
    • Nasal congestion (15-20%)
    • Decreased or increased libido (10-15%)
    • Menstrual disorder (10-15%)
    • Difficult micturition (10-15%)

    1-10% (4 mg dose)

    • Tachycardia (5-10%)
    • Confusion (5-10%)
    • Insomnia (5-10%)
    • Nausea/vomiting (5-10%)
    • Blurred vision (5-10%)
    • Nasal congestion (5-10%)
    • Hypotension (1-5%)
    • Syncope (1-5%)
    • Akathisia (1-5%)
    • Dizziness (1-5%)
    • Increased salivation (1-5%)
    • Nervousness (1-5%)
    • Tremor (1-5%)
    • Weight change (1-5%)

    1-10% (10 mg dose)

    • Increased salivation (5-10%)
    • Talkativeness (1-5%)
    • Incontinence (1-5%)

    Anterograde amnesia reported with benzodiazepine use

    Use caution in elderly patients

    Use caution in debilitated patients

    Use caution in severe respiratory depression; if signs and symptoms of respiratory depression, hypoventilation, or apnea occur, discontinue

    Use caution in patients who recently received other respiratory depressants

    Use caution in patients who are at risk of falls

    May have prolonged effects in obese patients when discontinued; use caution

    Not for us in acute alcohol intoxication

    Use with caution in patients with hepatic or renal impairment

    Myasthenia gravis (allowable in limited circumstances)

    Use caution in cases of respiratory disease (COPD), sleep apnea, renal/hepatic disease, open-angle glaucoma (questionable), depression, suicide ideation, drug abuse

    CNS depressant; may impair ability to perform hazardous tasks

    Paradoxical reactions, including hyperactive or aggressive behavior reported

    Cigarette smoking may decrease alprazolam concentration up to 50%

    Mania and hypomania episodes reported in depressed patients

    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to drug during pregnancy

    Limited data from published literature reports the presence of the drug in human breast milk; there are reports of sedation and withdrawal symptoms in breastfed neonates and infants exposed to alprazolam; effects of alprazolam on lactation are unknown

    Adults

    10 mg/day PO.

    Geriatric

    10 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    Alprazolam

    tablet: Schedule IV

    • 0.25mg

    • 0.5mg

    • 1mg

    • 2mg

    tablet, extended-release: Schedule IV

    • 0.5mg

    • 1mg

    • 2mg

    • 3mg

    tablet, orally disintegrating: Schedule IV

    • 0.25mg

    • 0.5mg

    • 1mg

    • 2mg

    oral solution: Schedule IV

    • 1mg/mL